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Abstract
Background: Recent in vitro evidence indicates that blockade of 5-hydroxytryptamine (5-HT)
receptor 3 (5-HT3) is able to confer protection in different models of neuronal injury. The purpose
of the present study was to investigate the effect of tropisetron, a 5-HT3 receptor antagonist, on
infarct size and neurological score in a model of ischemic stroke induced by permanent middle
cerebral artery occlusion (pMCAO) in the rat.
Methods: Two different doses of tropisetron (5 and 10 mg/kg) or vehicle were administered
intraperitoneally 30 min before pMCAO. Neurological deficit scores, mortality rate and infarct
volume were determined 24 h after permanent focal cerebral ischemia.
Results: Tropisetron failed to reduce cerebral infarction. Animals receiving tropisetron showed a
significant increase (p < 0.05) in neurological deficits and mortality rate.
Conclusion: Data from this study indicate that blockade of 5-HT3 receptors with tropisetron
worsens ischemic brain injury induced by pMCAO. These findings could have important clinical
implications. Patients taking tropisetron, and possibly other 5-HT3 antagonists, could potentially
have a worse outcome following a brain infarct.
Background
Stroke is a leading cause of death and disability worldwide
[1,2]. Although significant efforts have been devoted to
understand the pathophysiology of cerebral ischemia,
very few therapeutic options are available [3]. Among the
deleterious events following occlusion of a blood vessel in
the brain, excitotoxicity and alteration of intraneuronal
Ca2+  homeostasis are considered early processes that
propagate the cascade of harmful events leading to cere-
bral infarction [4,5]. The primary ischemic episode results
in neuroinflammation, which leads to increase in tissue
destruction through mechanisms involving oxidative
stress, upregulation of pro-inflammatory cytokines (TNF-
α, IL-1β), enhanced metabolism of arachidonic acid,
breakdown of the blood-brain barrier, and edema [6-8].
Recently, there has been much interest in the potential
neuroprotective efficacy of 5-hydroxytryptamine (5-HT)
receptor subtype 3 (5-HT3) antagonists [9,10]. Blockade
of 5-HT3 receptor with MDL72222 and Y-25130 reduced
Published: 6 February 2008
BMC Neuroscience 2008, 9:19 doi:10.1186/1471-2202-9-19
Received: 12 October 2007
Accepted: 6 February 2008
This article is available from: http://www.biomedcentral.com/1471-2202/9/19
© 2008 Candelario-Jalil et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neuroscience 2008, 9:19 http://www.biomedcentral.com/1471-2202/9/19
Page 2 of 6
(page number not for citation purposes)
glutamate release, elevation of cytosolic Ca2+ concentra-
tion, oxidative damage, and apoptotic neuronal cell death
induced by either hydrogen peroxide or β-amyloid pep-
tide [9,10]. Furthermore, an earlier study by Kagami-ishi
and colleagues demonstrated that the 5-HT3 antagonist Y-
25130 conferred protection against ischemia-induced
decrease in CA1 field potential in rat hippocampal slices
[11].
In the light of all this previous evidence, the present inves-
tigation was conducted to assess whether treatment with
the 5-HT3 antagonist tropisetron would show neuropro-
tective effect against cerebral ischemic injury. Since most
cases of human ischemic stroke are caused by irreversible
occlusion of major cerebral arteries [12-14], we utilized a
well-standardized model of permanent occlusion of the
middle cerebral artery (pMCAO) in the rat.
Results
Effect of tropisetron on infarct volume following 
permanent focal cerebral ischemia in the rat
Using the intraluminal filament technique, we had previ-
ously found that infarct size reached its maximal values at
24 h after pMCAO [15]. For this reason, in the present
investigation animals were studied at 24 h after the onset
of stroke. All animals studied had large infarct areas in the
MCA territory, involving both cortical and subcortical
structures, as revealed by the lack of TTC staining in these
regions (Fig. 1A). Pretreatment with two different doses of
the 5-HT3 antagonist, tropisetron, failed to reduce the
total infarct volume, as shown in Fig. 1B. To exclude the
possibility of a region-specific outcome, we next investi-
gated the effect of tropisetron on the infarct volume in
cortical and subcortical regions. Again, tropisetron did not
significantly modify the size of the infarct in this animal
model of stroke (Fig. 1B). Similarly, we studied the rostr-
ocaudal distribution of areas of cortical and subcortical
infarction at six coronal levels in tropisetron- and vehicle-
treated rats. No effect of tropisetron was observed at any
level of the brain infarct (data not shown). Furthermore,
among treatment groups, there were no statistically signif-
icant differences in the edema index (Vehicle: 1.033 ±
0.028; Tropisetron 5 mg/kg: 1.031 ± 0.013; and Tropiset-
ron 10 mg/kg: 1.039 ± 0.018).
Ischemic animals receiving tropisetron showed increased 
neurological deficits and mortality
Animals given tropisetron displayed a significant increase
in the neurological deficits at 24 h after pMCAO.
Although administration of 5 mg/kg of tropisetron did
not significantly modify neurological scores, treatment of
rats with 10 mg/kg of tropisetron 30 min before pMCAO
produced a significant deterioration of the neurological
status in these animals (Fig. 2A). Furthermore, in animals
receiving the highest dose of tropisetron, there was a sig-
nificant (p = 0.0089; Χ2 test) increase to 55.5% (5 of 9
rats) in the mortality rate compared to vehicle-treated ani-
mals (8.3%; 1 of 12 rats), as shown in Fig. 2B. There was
a trend towards an increase in mortality in rats receiving 5
mg/kg of tropisetron, but this effect did not reach statisti-
cal significance (p = 0.0518; Χ2 test).
Discussion
Present data do not support the notion that blockade of 5-
HT3 receptors reduces ischemic brain injury induced by
focal cerebral ischemia. On the contrary, our findings
clearly showed that treatment with tropisetron worsened
neurological recovery and increased mortality of ischemic
animals. No previous investigations have been published
on the effects of the 5-HT3 antagonist tropisetron on neu-
ronal damage induced by focal cerebral ischemia. Thus,
these in vivo data could have important implications for
the potential use of 5-HT3 antagonists in neuroprotection,
as other investigators have suggested [9-11]. Most 'nega-
tive' results in preclinical studies in cerebral ischemia are
not even submitted for publication. This practice goes
against the STAIR (Stroke Therapy Academic Industry
Roundtable) recommendations that data, both positive
and negative, should be published [16-18].
(A): Representative TTC-stained sections of vehicle- and  tropisetron-treated rats at 24 h following permanent middle  cerebral artery occlusion (pMCAO) Figure 1
(A): Representative TTC-stained sections of vehicle- 
and tropisetron-treated rats at 24 h following perma-
nent middle cerebral artery occlusion (pMCAO). 
Tropisetron or vehicle was given intraperitoneally 30 min 
before pMCAO. (B): Total, cortical and subcortical infarct 
volumes assessed at 24 h in control (vehicle) and tropisetron 
groups. No significant effect of tropisetron on cerebral inf-
arction was found.BMC Neuroscience 2008, 9:19 http://www.biomedcentral.com/1471-2202/9/19
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Previous studies evaluating the neuroprotective efficacy of
5-HT3 antagonists utilized in vitro cultures of neurons and
hippocampal slices subjected to ischemia-like conditions.
Those findings indicated that blockade of 5-HT3 receptors
might confer significant neuroprotection by reducing
glutamate release, free radicals formation, and mainte-
nance of Ca2+ homeostasis [9,10].
It is well established that the activation of 5-HT3 receptors
is followed by rapid depolarization causing rapid rise in
cytosolic Ca2+ levels by inducing influx of Ca2+ and mobi-
lization of intracellular Ca2+ stores [19]. These processes
modulate the release of various neurotransmitters includ-
ing dopamine, glutamate, acetylcholine, GABA and 5-HT
itself [19,20].
We had previously shown that tropisetron potently inhib-
its lipopolysaccharide-mediated production of TNF-α and
IL-1β in human monocytes, as well as 5-HT-induced pros-
taglandin E2 (PGE2) release from synovial cells [21,22]. In
addition, we found that tropisetron inhibited DNA bind-
ing and transcriptional activity of NFAT, AP-1 and NF-κB
in T cells exposed to pro-inflammatory stimuli [23]. Fur-
thermore, very recent data from our lab indicate that the
5-HT3  antagonists, tropisetron, ondansetron and
dolansetron, significantly reduce PGE2 release and 8-iso-
prostane formation (a reliable marker of free radical gen-
eration) in neuronal cells exposed to IL-1β (Fiebich et al.,
manuscript in preparation).
Based on this promising evidence coming from in vitro
studies, one might expect that blockade of 5-HT3 receptors
to be beneficial in cerebral ischemia. However, results
from this investigation not only demonstrate that treat-
ment with tropisetron failed to diminish brain infarction,
but also showed that neurological deficits and mortality
rate were dramatically increased in ischemic animals
given this 5-HT3 antagonist. At present, the molecular
mechanisms underlying these detrimental effects of tropi-
setron are far from clear. In addition, it is not yet known
whether other 5-HT3 antagonists share these stroke-wors-
ening properties of tropisetron.
One possible explanation for these detrimental effects of
tropisetron might be the ability of 5-HT3 antagonists to
significantly reduce GABAergic neurotransmission
[24,25]. This notion is based on evidence showing that
Ca2+ influx through presynaptic 5-HT3 receptors facilitates
GABA release in several brain regions [25,26]. Cerebral
ischemia produces a dramatic increase in GABA release,
which is thought to be an important compensatory mech-
anism against ischemia [27]. Activation of GABA receptors
potently reduces ischemic and excitotoxic brain injury
[27]. Thus, blockade of 5-HT3 receptors with tropisetron
could potentially hamper this protective mechanism
involving ischemia-mediated GABA release. However, this
possibility should be confirmed experimentally in a
model of ischemic stroke.
Antagonists of 5-HT3 receptors, including tropisetron, are
clinically used for the management of postoperative nau-
sea and vomiting (PONV), and for the treatment of chem-
otherapy-induced nausea and emesis. These drugs
selectively and competitively bind to 5-HT3 receptors,
blocking serotonin binding at vagal afferents in the gut
and in the regions of the central nervous system involved
in emesis, including the chemoreceptor trigger zone and
the nucleus tractus solitarii [28,29].
It is difficult to ascertain whether the doses of tropisetron
used here in the rat are comparable to the dosage used in
Effect of the 5-HT3 antagonist tropisetron on neurological  deficits scores (A) and mortality rate (B) after pMCAO Figure 2
Effect of the 5-HT3 antagonist tropisetron on neuro-
logical deficits scores (A) and mortality rate (B) after 
pMCAO. Animals received a single i.p. injection of tropiset-
ron or the vehicle 30 min before being subjected to pMCAO. 
Twenty-four hours later, neurological scores were evaluated 
following a 6-point scale as detailed in Materials and Meth-
ods. Median neurological score is marked in Panel A by a 
small horizontal bar. Mortality rate is presented as percent-
age (%). *p < 0.05 with respect to vehicle-treated animals.BMC Neuroscience 2008, 9:19 http://www.biomedcentral.com/1471-2202/9/19
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humans. A direct interspecies dose extrapolation is usu-
ally inaccurate due to changes in the pharmacokinetic/
pharmacological behavior of the drug in different species
[30]. This is further complicated by the fact that some 5-
HT3  antagonists, including tropisetron, show a bell-
shaped dose-response curve [20], leaving open the possi-
bility that lower doses of tropisetron might have complete
different effects in permanent ischemic stroke.
Significant increase in neurological deficits and mortality
was found in animals receiving tropisetron. However, no
parallel increase in infarct size was observed in any of the
groups treated with tropisetron when compared to rats
given the vehicle. There is not always a direct correlation
between the lesion size and the severity of neurological
deficits as demonstrated before in animal models [31,32]
and in stroke patients [33]. This indicates that the severity
of disability is not predicted well by the amount of brain
tissue lost.
Conclusion
In summary, this study showed that the 5-HT3 antagonist
tropisetron failed to reduce cerebral infarction induced by
pMCAO in the rat, and produced a significant increase in
neurological deficits and mortality rate. Whichever the
mechanism(s) responsible for the detrimental effects of
tropisetron in cerebral ischemia, present study could have
important clinical implications. Patients taking tropiset-
ron, and possibly other 5-HT3 antagonists, might have a
worse prognosis following a cerebral ischemic event.
Methods
Animals
Male Sprague-Dawley rats weighing 280–320 g at the time
of surgery were obtained from Harlan Spain (Harlan
Interfauna Iberica S.A., Barcelona, Spain). Our institu-
tional animal care and use committee approved the exper-
imental protocol. The animals were quarantined for at
least 7 days before the experiment. Animals were housed
in groups in a room whose environment was maintained
at 21–25°C, 45–50% humidity, and 12-h light/dark cycle.
They had free access to pellet chow and water. Animal
housing, care, and application of experimental procedures
were in accordance with institutional guidelines under
approved protocols.
Induction of permanent middle cerebral artery occlusion 
(pMCAO) in the rat
Rats were anesthetized with chloral hydrate (300 mg/kg
body weight, i.p.). Once surgical levels of anesthesia were
attained (assessed by absence of hind leg withdrawal to
pinch), ischemia was induced by using an occluding intra-
luminal suture as described previously [31,34,35]. Briefly,
the right common carotid artery (CCA) was exposed by a
ventral midline neck incision and ligated with a 3-0 silk
suture. The pterygopalatine branch of the internal carotid
artery was clipped to prevent incorrect insertion of the
occluder filament. Arteriotomy was performed in the CCA
approximately 3 mm proximal to the bifurcation and a sil-
icone rubber coated 4-0 nylon filament (Doccol Corpora-
tion, Redlands, CA, USA) was introduced into the internal
carotid artery (ICA) until a mild resistance was felt (18–19
mm). Mild resistance to this advancement indicated that
the intraluminal occluder had entered the anterior cere-
bral artery and occluded the origin of the anterior cerebral
artery, the middle cerebral artery (MCA) and posterior
communicating arteries [36]. After the advancement of
the nylon suture, the ICA was firmly ligated with a 3-0 silk
suture. The incision was closed and the occluding suture
was left in place until sacrificing the animals. The duration
of surgery did not exceed 12 min in any case. The animals
were allowed to recover from anesthesia and to eat and
drink freely. The body temperature was strictly controlled
during and after ischemia using an overhead lamp and a
heating blanket. No significant effect of tropisetron on
body temperature was observed (data not shown). To
allow for better postoperative recovery, we chose not to
monitor physiological parameters in the present study
because additional surgical procedures are needed for this
monitoring.
Evaluation of neurological deficits
After 24 h of pMCAO, an unaware independent observer
performed the neurological evaluations prior to the sacri-
fice of the animals according to a six-point scale: 0 = no
neurological deficits, 1 = failure to extend left forepaw
fully, 2 = circling to the left, 3 = falling to left, 4 = no spon-
taneous walking with a depressed level of consciousness,
5 = death [36,37].
Quantification of brain infarct volume
The size of the brain infarct was assessed at 24 h following
pMCAO. The method for quantification of infarct volume
was performed exactly as described in these reports
[15,35,38,39]. Briefly, the animals were sacrificed under
deep anesthesia and brains were removed, frozen, and
coronally sectioned into six 2-mm-thick slices (from ros-
tral to caudal, first to sixth) using a rat brain matrix
(World Precision Instruments, Sarasota, FL, USA). The
brain slices were incubated for 30 min in a 2% solution of
2,3,5-triphenyltetrazolium chloride (TTC) (Sigma Chem-
ical Co., Saint Louis, MO, USA) at 37°C and fixed by
immersion in a 10% phosphate-buffered formalin solu-
tion. Six TTC-stained brain sections per animal were
placed directly on the scanning screen of a color flatbed
scanner (Hewlett Packard HP Scanjet 5370 C) within 7
days. Following image acquisition, the images were ana-
lyzed blindly using a commercial image processing soft-
ware program (Photoshop, version 7.0, Adobe Systems;
Mountain View, CA, USA). Measurements were made byBMC Neuroscience 2008, 9:19 http://www.biomedcentral.com/1471-2202/9/19
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manually outlining the margins of infarcted areas. The
unstained area of the fixed brain section was defined as
infarcted. Cortical and subcortical uncorrected infarcted
areas and total hemispheric areas were calculated sepa-
rately for each coronal slice. Total cortical and subcortical
uncorrected infarct volumes were calculated by multiply-
ing the infarcted area by the slice thickness and summing
the volume of the six slices. A corrected infarct volume
was calculated to compensate for the effect of brain
edema. An edema index was calculated by dividing the
total volume of the hemisphere ipsilateral to pMCAO by
the total volume of the contralateral hemisphere. The
actual infarct volume adjusted for edema was calculated
by dividing the infarct volume by the edema index
[40,41]. Infarct volumes are expressed as a percentage of
the contralateral (control) hemisphere. The investigator
who performed the image analysis was blinded to the
study groups.
Drug treatment
Animals were randomly allotted in three different groups:
tropisetron 5 mg/kg (n = 11), tropisetron 10 mg/kg (n =
9) and vehicle (physiological saline, n = 12). Drugs were
given intraperitoneally 30 min before inducing pMCAO.
These doses were selected based on previous studies dem-
onstrating effects of tropisetron in the central nervous sys-
tem [42,43]. In addition, the pharmacokinetic profile of
these doses of tropisetron has being well-characterized in
the rat [44]. Tropisetron was obtained from the in-house
pharmacy of the University of Freiburg Medical School
(Freiburg, Germany).
Data analysis
Data are presented as mean ± S.E.M. Values were com-
pared using t-test (two groups) or one-way ANOVA with
post-hoc Student-Newman-Keuls test (multiple compari-
son). Neurological deficit scores were analyzed by
Kruskal-Wallis non-parametric ANOVA followed by the
Dunn test (multiple comparison) or Mann-Whitney test
for analysis of individual differences. Mortality rate was
analyzed using Chi-square (Χ2) test. Differences were con-
sidered significant when p < 0.05.
List of abbreviations
ANOVA (analysis of variance); 5-HT (5-hydroxytryp-
tamine); pMCAO (permanent middle cerebral artery
occlusion); TTC (2,3,5-triphenyltetrazolium chloride).
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